Onconetix Corp - רווח נקי למניה בארבעת הרבעונים האחרונים ONCO

Onconetix, Inc. (ONCO) is implementing advanced diagnostic and therapeutic methods for men's health while minimizing side effects. The business is currently restructuring its client base, leveraging the distribution of specialized products. Revenues are based on the supply of targeted prostate treatment agents to clinics. The year-over-year EPS (TTM) history on the GURU.Markets chart demonstrates profit dynamics, where the value of 99.30 expresses the metric level.
onconetix.gcs-web.com - פילוחים אנליטיים ומדדי מפתח (ONCO)

This indicator measures the annual dynamics of net income per share, smoothing quarterly volatility via a twelve-month rolling window. Analyzing the 12-month YoY net income per share change allows for an assessment of the business's actual operational efficiency. The metric discounts the impact of costs on final shareholder returns. For Onconetix, Inc. (ONCO), this is critical when adapting assets following a merger. Investors use this chart to monitor pipeline commercialization and the stabilization of device sales.